VIVEX is expanding our Amnion & Wound Care Distribution Network. Interested in becoming a distribution partner? Click here to learn more.

NP PILOT STUDY
24-Month Durability Results
NRS: 64% of participants achieved a substantial clinical benefit (SCB) with >50% improvement in back pain at 24 months (p<0.001).
ODI: 73% of participants achieved a minimal clinically important difference (MCID) of > 30% improvement in ODI from baseline to 24 months (p<0.001).
Functional Improvement: At baseline, 82% of participants reported severe or crippled back impairment compared to 18% at 24 months (p<0.001).
Read the 6-Month Study
Read the 12-Month Study
Read the 24-Month Study
Read the full publication(s) for complete study results, adverse events, and safety-related information.
6-Month: Beall DP, Davis TT, Amirdelfan K, et al. Nucleus Pulposus Allograft Supplementation in Patients with Lumbar Discogenic Pain: Initial 6-month Outcomes from a Prospective Clinical Pilot Study. Pain Physician. 2024;27(8):E865-E871.
12-Month: Beall DP, Davis TT, Amirdelfan K, et al. Supplemental nucleus pulposus allograft in patients with lumbar discogenic pain: results of a prospective feasibility study. BMC Musculoskeletal Disorders. 2025;26(1):437. Published 2025 May 1. doi:10.1186/s12891-025-08701-0
24-Month: Costandi S, Beall DP, Davis TT, et al. Durability of Supplemental Nucleus Pulposus Allograft in Patients with Lumbar Discogenic Pain. Journal of Pain Research. 2025;18:1901-1908. Published 2025 Apr 9. doi:10.2147/JPR.S516571
OPP STUDY
6-Month Outcomes in Medicare Beneficiaries
NRS: Statistically significant 60% reduction in back pain between baseline and 6 months, with 82% of participants achieving MCID of > 30% reduction in pain (p<0.001).
ODI: 6-month improvement in mean ODI scores was 50%, with 68% of participants achieving MCID
of > 30% improvement in function (p<0.001).
Functional Improvement: At baseline, 53% of participants reported severe or crippled back impairment compared to 11% at 6 months (p< 0.001).
Read the 6-Month Study
Read the full publication for complete study results, adverse events, and safety-related information.
6-Month: Azeem N, Myers TJ, Tate JL, Gilmore CA, Harper AS, Block JE. Supplemental Nucleus Pulposus Allograft in Patients with Lumbar Discogenic Pain: Evaluation of Clinical Outcomes and Quality of Life in Medicare Beneficiaries. Clinical Interventions in Aging. 2025;20:717-726. Published 2025 May 27. doi:10.2147/CIA.S523457
PUBLICATIONS
Defining the Patient with Lumbar Discogenic Pain: Real World Implications for Diagnosis and Effective Clinical Management
Lorio MP, Beall DP, Calodney AK, Lewandrowski KU, Block JE, Mekhail N. Journal of Personalized Medicine. 2023;13(5):821. Published 2023 May 12. doi:10.3390/jpm13050821
Read the Study
Perspective on Intradiscal Therapies for Lumbar Discogenic Pain: State of Science, Knowledge Gaps, and Imperatives for Clinical Adoption
Lorio MP, Tate JL, Myers TJ, Block JE, Beall DP. Journal of Pain Research. 2024;17:1171-1182. Published 2024 Mar 18. doi:10.2147/JPR.S441180
Read the Study
The Role of ISASS in evolving the Spine Code Landscape: Lumbar Discogenic Pain Receives Specific ICD-10-CM Code
Lorio MP, Yuan HA, Beall DP, Block JE, Andersson GBJ. International Journal of Spine Surgery. 2024;18(4):353-354. Published 2024 Sep 12. doi:10.14444/8622
Read the Study
Successful Intradiscal Treatment of Adjacent Segment with VIA Disc NP Allograft in a 65-Year-Old Woman with L4-Sacrum Laminectomy and Posterior Fusion
Myers, T. J. Pain Medicine Case Reports. The American Society of Interventional Pain Physicians., 2022, 6, 229-233.
Read the Study
A Proposed Diagnostic and Treatment Algorithm for the Management of Lumbar Discogenic Pain
Lorio MP, Beall DP, Myers TJ, et al. Journal of Pain Research. 2025;18:3331-3343. Published 2025 Jul 1. doi:10.2147/JPR.S522750
Read the Study